AzTrials
AzTrials

Gingival BleedingNCT03078595

Gingival Bleeding and Von Willebrand Disease Typ 2 and 3

An observational study of Gingival Bleeding and Von Willebrand Diseases, run by Goethe University at 2 sites in Germany.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Von Willebrand disease (VWD) is the most common inherent bleeding disorder resulting in prolonged bleeding time. Gingival bleeding is a frequently reported symptom of VWD. However, gingival bleeding is also known as a leading symptom of plaque-induced gingivitis and untreated periodontal disease. Read more about this study

Who is it for?
Ages 18 to 80 yearsHealthy volunteers can take part
Conditions the study is for
Gingival Bleeding, Von Willebrand Diseases
Type of treatment
Pill or oral medicine
How many people
48 participants
Where
2 sitesGermany
Study dates
16 Jul 2015to 4 Apr 2017
Phase
Observational
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Cases with type 2 and 3 VWD consecutively consulting the Haemophilia Centre, Medical Clinic III/Institute for Transfusion medicine, Hospital of the Johann Wolfgang Goethe-University Frankfurt/Main are asked to participate in this study as cases. For each case (VWD) a respective haematologically healthy matched control is recruited from the gingivitis and periodontitis patients of the Department of Periodontology, Centre for Dentistry and Oral Medicine (Carolinum), Johann Wolfgang Goethe-University Frankfurt/Main.

Who may be able to join

  • 18 - 80 years old
  • no other bleeding disorder except 2 and 3 von Willebrand disease
  • no bleeding disorder
  • no anticoagulative medication

Who cannot join

  • requirement of systemic antibiotics for measures that may cause transitory bacteraemia
  • bleeding disorder

Trial locations and contacts

2 sites in 1 country.

Germany2 sites
  • Center for Dentistry and Oral Medicine (Carolinum), Johann Wolfgang Goethe-University

    Frankfurt am Main, Hesse, 60596

  • Dept. of Periodontology, Center of Dentistry and Oral Medicine, Johann Wolfgang Goethe-University

    Frankfurt am Main, 60590

Other trials in Germany

About this study

Official title: Is Gingival Bleeding a Symptom of Patients With Type 2 and 3 Von Willebrand Disease? A Case-Control Study

Von Willebrand disease (VWD) is the most common inherent bleeding disorder resulting in prolonged bleeding time. Gingival bleeding is a frequently reported symptom of VWD. However, gingival bleeding is also known as a leading symptom of plaque-induced gingivitis and untreated periodontal disease. Gingival bleeding in VWD patients may be triggered by gingival inflammation and not a genuine symptom. Thus, this study evaluates whether type 2 and 3 VWD determines an increased susceptibility to gingival bleeding in response to the oral biofilm.

Read the detailed description

Patients

All patients with type 2 and 3 VWD consecutively consulting the Haemophilia Centre, Medical Clinic III/Institute for Transfusion medicine, Hospital of the Johann Wolfgang Goethe-University Frankfurt/Main are asked to participate in this study as cases. They are asked for bleeding and subjective symptoms indicating periodontal disease.

The study complies with the rules of the Declaration of Helsinki and was approved by the Institutional Review Board for Human Studies of the Medical Faculty of the Goethe-University Frankfurt/Main (Application# 143/15). All participating individuals are informed on risks and benefits as well as the procedures of the study and give written informed consent.

Controls

For each case (VWD) a respective hematologically healthy control is recruited from the gingivitis and periodontitis patients of the Department of Periodontology, Centre for Dentistry and Oral Medicine (Carolinum), Johann Wolfgang Goethe-University Frankfurt/Main. Each control is matched to one of the respective cases for sex, age (±5 years), self-reported smoking status (current smoker/non-smoker), number of remaining teeth (±2 teeth), and periodontal diagnosis (gingivitis, chronic or aggressive periodontitis).

All participants are asked about current and past cigarette smoking habits. Patients who report smoking or have quit smoking for less than five years are classified as smokers. Additionally the amount of carbon monoxide (CO) in exhaled air is measured using a device (Bedfont Smokerlyzer; Bedfont Scientific Ltd, Rochester, Great Britain).

Hematologic examinations

20 ml of blood are sampled from an arm vein. The following data are assessed at the Haemophilia Centre for clinical routine during VWD patient care and due to study design in the controls:

  • von Willebrand parameters (VWF antigen [VWF:Ag], Ristocetin cofactor [VWF:RCo], coagulation factor VIII [FVIII:C])
  • Current medication if any VWF:Ag and VWF:RCo were measured turbidimetrically using a device (BCS, Siemens, Marburg, Germany). FVIII:C was assessed with specific agents on a coagulation analyser (ACL-300®, Instrumentation Laboratory, Kirchheim, Germany).

Periodontal examinations

The following clinical parameters are assessed at 6 sites per tooth (mesiobuccal, buccal, distobuccal, mesiolingual, lingual, distolingual):

  • modified Gingival Bleeding Index (GBI)
  • modified Plaque Control Record (PCR)
  • PPD and recession to the nearest 0.2 mm using an electronic probe (Florida Probe, Version 3.2, Gainesville, USA). Recession is assessed from the cemento-enamel junction (CEJ) to the gingival margin. At sites where the CEJ was destroyed by restorations the restoration margin (RM) is used as reference. At sites where the CEJ or RM is located apically from the gingival margin the value for recession is negative
  • Bleeding on probing (BOP) recorded as positive when bleeding occurs within 30 seconds from probing. For each patient a BOP index is calculated providing the amount of sites with positive BOP in % per patient.

Attachment loss (PAL-V) is calculated as sum of PPD and recession.

All individuals are classified into the following diagnoses:

  • plaque-induced gingivitis (PPD < 3.6 mm; PAL-V ≤ 2 mm),
  • generalized mild, localized moderate chronic periodontitis (PPD ≥ 3.6 mm; vertical probing attachment level [PAL-V] 3 to 4 mm ≤ 30% of sites; 1 to 2 mm > 30% of sites),
  • generalized mild, localized severe chronic periodontitis (PPD ≥ 3.6 mm; PAL-V ≥ 5 mm ≤ 30% of sites; 1 to 2 mm > 30% of sites)
  • generalised moderate chronic periodontitis (PPD ≥ 3.6 mm; PAL-V 3 to 4 mm > 30%)
  • generalised moderate localised severe chronic periodontitis (PPD ≥ 3.6 mm; PAL-V 3 to 4 mm > 30%; ≥ 5 mm ≤ 30%)

In all individuals hematological and periodontal examinations are obtained within 24 hours. After dental and periodontal examination all patients receive oral hygiene instructions and professional tooth cleaning. In cases of untreated periodontal disease periodontal treatment is offered. VWD are asked to report any bleeding complications after periodontal probing and professional tooth cleaning.

Statistical analysis

The individual patient is used as statistical unit. All analyses are performed on patient level. GBI is defined as the main outcome variable and BOP as secondary outcome variable. All other parameters are control variables. Up to now there are no studies comparing GBI or BOP between VWD type 2 and 3 cases and hematologically healthy controls and there are no standard deviations of mean GBI and BOP for cases and controls. To detect a clinically relevant inter-group difference of 4% GBI or BOP with a type 1 error alpha < 0.05 and a test power of 80% with a standard deviation of group means of 5.5% a sample size of at least 31 individuals is required per group. Thus, it was decided to recruit 31 VWD cases and respectively matched 31 controls.

For all individuals, cigarette pack years are calculated. Group frequencies (VWD, control) are expressed for sex, current smoking. Group means and standard deviations are calculated for GBI, BOP, age, number of remaining teeth, pack years, CO, PCR, VWF:Ag, VWF:RCO, FVIII:C. Further, for each individual the following variables are calculated to describe the periodontal status:

  • Mean±standard deviation of PPD and PAL-V
  • Percentage of PPD < 4 mm, 4 to 6.8 mm, ≥ 7 mm
  • Sum of all PPD, i.e. the sum of the PPD measured at all sites within a patient
  • Sum of all PPD with BOP, ), i.e. the sum of the PPD measured at all sites exhibiting BOP within a patient
  • Periodontal inflamed surface area (PISA). For each patient PPD were entered into an Excel sheet that can be downloaded freely (http://www.parsprototo.info/pisa.html).

From these group means and standard deviations are calculated. Comparisons between groups for dichotomous parameters are made by χ² or Fisher's exact test and for all other parameters by Mann-Whitney-U test. A post-hoc analysis is performed to estimate the test power that would be required to find a clinically relevant inter-group difference (δ) of 5% for GBI and BOP index with a type 1 error (α) of 0.05 for the actual sample size.

Using stepwise linear backward multiple regression analysis, factors shall be identified that influence GBI and BOP. The following independent variables are entered into the model for GBI: group (VWD/control), sex, age, number of remaining teeth, PCR, CO, pack years, PISA. The following independent variables are entered into the model for BOP: group (VWD/control), sex, age, number of remaining teeth, PCR, CO, pack years, PISA. Due to the fact that mean PPD is mathematically coupled to sum of PPD, sum of PPD with BOP, and PISA these 4 variables are not entered into the regression model at the same time. PISA provides the best representation of the subgingival inflamed area. Thus, PISA is chosen for the final model. The following parameters are described by dummy variables: group (control = 0, VWD = 1), sex (male = 0, female = 1), smoking status (never and former smoker = 0, current smoker = 1). All factors with p < 0.1 are kept in the models. For statistical analysis a PC program is used (SystatTM for Windows Version 12, Systat Inc., Evanston, USA).

Keywords
periodontal disease, plaque-induced gingivitis, bleeding on probing, von willebrand disease, gingival bleeding
Medical subject headings
Gingival Hemorrhage, von Willebrand Diseases, Periodontal Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT03078595
Study groupRoleWhat they receive
von Willebrand disease type 2 and 3Examinations (haematologically and periodontally) of von Willebrand disease patients with type 2 and 3 and healthy controls to evaluate whether type 2 and 3 VWD determines an increased susceptibility to gingival bleeding in response to the oral biofilm
controlsFor each case (VWD) a respective haematologically healthy control is recruited from the gingivitis and periodontitis patients of the Department of Periodontology, Centre for Dentistry and Oral Medicine (Carolinum), Johann Wolfgang Goethe-University Frankfurt/Main. Each control is matched to one of the respective cases for sex, age (±5 years), self-reported smoking status (current smoker/non-smoker), number of remaining teeth (±2 teeth), and periodontal diagnosis (gingivitis, chronic or aggressive periodontitis).

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Bleeding on Probing (BOP)

    Using a periodontal probe probing pocket depths (PPD) are assessed with a force of 0.2 N at 6 sites per tooth (mesio-buccal, buccal, disto-buccal, disto-oral, oral, mesio-oral). After 30 seconds bleeding on probing is scored at each site. The frequency of bleeding sites of the total number of assessed sites is calculated as index.

    Measured: cross-sectional: only one assessment at the time of examination

Secondary outcomes (1)
  1. Gingival Bleeding Index (GBI)

    A periodontal probe is gently moved through the gingival sulcus. Bleeding is assessed at 6 sites per tooth (mesio-buccal, buccal, disto-buccal, disto-oral, oral, mesio-oral). The frequency of bleeding sites of the total number of assessed sites is calculated as index.

    Measured: cross-sectional: only one assessment at the time of examination

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Mar 2017
  2. Study start16 Jul 2015
  3. Primary completion4 Apr 2017
  4. Study completion4 Apr 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
48 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03078595
Sponsor's protocol ID
143/15
Status last verified
Feb 2020
First submitted
1 Mar 2017
Last updated
27 Feb 2020
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Epping L, Miesbach W, Nickles K, Eickholz P. Is gingival bleeding a symptom of type 2 and 3 von Willebrand disease? PLoS One. 2018 Jan 25;13(1):e0191291. doi: 10.1371/journal.pone.0191291. eCollection 2018.

    PubMed 29370241

Questions about this trial

What is this clinical trial studying?

An observational study of Gingival Bleeding and Von Willebrand Diseases, run by Goethe University at 2 sites in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Feb 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 27 Feb 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Bleeding on Probing (BOP) (time frame: cross-sectional: only one assessment at the time of examination). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03078595, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Feb 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in